Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple. Comparación con el sistema de Durie-Salmon

Information of 81 patients aged 38 to90 years (43 women) was retrieved. According D&S system 11% were in stage I, 12% in stage II and73% in stage III. According to ISS, 34% were in stage I, 35% in stage II and 31% in stage III. Medianof survival of all patients was 32 months. Both staging systems had a prognostic value. However,median survival for the three stages of the ISS system was significantly different (67, 29 and 14months in stages I, II and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS,had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages IIand III of ISS the presence of renal failure was associated with a non significantly different lowersurvival.